Denis O. Shatalov

Denis O. Shatalov


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2024 in Sciences of Pharmacy
Verified
Journal Article
Open access
PDF file
IIIvan S. Ivanov
Ivan S. Ivanov
DKDaria Kirillova
Daria Kirillova
KEKenes Erimbetov
Kenes Erimbetov
DSDenis O. Shatalov
Denis O. Shatalov
Polyhexamethylene guanidine (PHMG) is a commonly used disinfectant, but safety concerns have arisen due to poisoning cases. This systematic review assesses the toxicity and safety of PHMG by inhalation, oral administration, skin contact, and ocular contact to determine its potential medical applications and acceptable concentration limits. Searches in PubMed, ScienceDirect, CENTRAL, and CyberLeninka up to January 2024 identified 11 in vitro studies with human cell lines, 28 animal studies, and 10 articles involving patients and healthy volunteers. The review found that inhalation of PHMG leads to pulmonary fibrosis and malignant neoplasms, making aerosol forms unacceptable. PHMG can also affect liver function and have adverse effects on the heart, kidneys, and hematopoietic system. For dermal use, PHMG appears to be safe at concentrations up to 3%, although practical use may limit this to 1% due to potential discomfort. Still, it is important to consider possible sensitization, especially in patients with pre-existing skin conditions. In oral hygiene, 1% PHMG-P has been used safely in periodontal treatment, suggesting its potential in dentistry. For ophthalmic use, concentrations should be carefully monitored. PHMG-P solutions below 0.13% appear to be safe for human corneal epithelium, however lower concentrations still pose a risk of corneal fibrosis, as shown in animal studies. Physicians should prefer lower concentrations and consider alternatives or formulations with reduced toxicity for sensitive applications such as eye drops. Overall, although PHMG and its derivatives show promise in a variety of medical applications, their use should be reasonable, with careful consideration of the associated risks.

26 July 2017 in Polymer Science, Series D
Verified
Journal Article
Closed access
PDF file
DSDenis O. Shatalov
Denis O. Shatalov
SKS. A. Kedik
S. A. Kedik
EZE. S. Zhavoronok
E. S. Zhavoronok
AAA. V. Aydakova
A. V. Aydakova
IIIvan S. Ivanov
Ivan S. Ivanov
EME. N. Mikhailenko
E. N. Mikhailenko
The review presents data regarding the main classes of substances applied in pharmaceutics for long-term control of pathogenic microflora. The problems of application of these substances caused by...

22 December 2023 in Sciences of Pharmacy
Verified
Journal Article
Open access
PDF file
IIIvan S. Ivanov
Ivan S. Ivanov
DADiana Akhmedova
Diana Akhmedova
YKYulia Anatolyevna Koroleva
Yulia Anatolyevna Koroleva
DSDenis O. Shatalov
Denis O. Shatalov
Preservatives in eye drops, while not always necessary, can lead to undesirable effects. Developing preservative-free solutions demands special measures for sterility, utilizing multidose or monodose primary packaging. This review explores the merits and drawbacks of these packaging types. A literature search on PubMed, Google Scholar, and EMBASE until December 2023, using MESH terms, yielded 28 studies on multidose ampoules and 24 on monodose packaging. Heterogeneous data revealed advantages and disadvantages concerning patient use and manufacturing. Chronologically presenting the development of eye drop packaging, this study finds Droptainer® simple but unable to maintain sterility. Comod®, 3K®, ABAK®, Novelia®, and Ophthalmic Squeeze Dispenser show high sterility probability, with Comod® and ABAK® having a contamination risk. Novelia® excels with long-term sterility and better control. Ophthalmic Squeeze Dispenser, FDA-approved, boasts a smaller carbon footprint. Unit-dose systems preserve sterility and offer design flexibility. Proposing an alternative, blister technology maintains sterility, is convenient and safe, and holds promise for recycling. This comprehensive assessment aids in understanding the evolving landscape of eye drop packaging, emphasizing the importance of sterility, convenience, and environmental impact.

7 July 2020 in Fine Chemical Technologies
Verified
Journal Article
Open access
PDF file
IIIvan S. Ivanov
Ivan S. Ivanov
DSDenis O. Shatalov
Denis O. Shatalov
SKS. A. Kedik
S. A. Kedik
ISI. P. Sedishev
I. P. Sedishev
SBSergei V. Beliakov
Sergei V. Beliakov
VKV. V. Komarova
V. V. Komarova
Objectives. Given that microorganisms can become resistant to certain groups of drugs and considering also their ability to form biofilms, the development of new drugs that are active against adapted microflora is required. This study focused on the development of a new method for the synthesis of a promising compound, the branched hydrosuccinate oligohexamethylene guanidine (OHMGsucc), with high purity that meets the standards of the 14th edition State Pharmacopeia of the Russian Federation (SPRF). Previously proposed methods have managed to isolate this product, which, however, complies with the requirements of the outdated SPRF. Therefore, the main aim of this study was to update the regulatory framework for the indicated OHMG salt for its further use in the pharmaceutical industry according to modern standards.Methods. To control the residual impurities of hexamethylenediamine (HMDA) and guanidine hydrochloride (GHC), high-performance liquid chromatography (HPLC) was applied using a Thermo Scientific Dionex UltiMate 3000 chromatograph, and the chromatographic signals of the test solution with those of a standard sample solution obtained by a previously published conventional method were compared.Results. The HPLC experimental data indicated a significant difference in the quantitative content of HMDA and GHC observed for the new and older preparation method of the branched OHMGsucc, suggesting that the method disclosed in this article can be used to obtain highly pure OHMGsucc.Conclusions. The specified compound was standardized with the parameter “related impurities” according to the current (14th) edition of the SPRF. The effectiveness and reproducibility of the proposed method was experimentally confirmed. In addition, a process diagram for the preparation of the indicated OHMG salt was prepared.

7 September 2022 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
IIIvan S. Ivanov
Ivan S. Ivanov
EBElena Bakhrushina
Elena Bakhrushina
ATAnastasia Romanovna Turaeva
Anastasia Romanovna Turaeva
DSDenis O. Shatalov
Denis O. Shatalov
AAAnna Viktorovna Aydakova
Anna Viktorovna Aydakova
SKStanislav Anatol’eVich Kedik
Stanislav Anatol’eVich Kedik
The purpose of this study is to find a unique ophthalmic packaging that takes into account modern requirements for both maintaining the quality and safety of the drug, compliance with therapy, and increasing the profitability and environmental friendliness of its production. Statistics from open international databases on drugs approved for ophthalmic therapy in 2022 are provided. The research criteria were a valid registration status, the type of packaging and the presence of a preservative in the composition of the eye drops. The results of statistical processing of databases of ministries of health of different countries have shown the relevance of monodose ophthalmic packaging, capable of long-term storage of the drug without preservatives. In many countries, particularly in Europe, many drugs in the form of a monodose containers are registered. On this basis, a unique aluminum-based monodose container design is proposed, eliminating the use of large quantities of plastic.

26 August 2020 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
SBSergei V. Beliakov
Sergei V. Beliakov
DSDenis O. Shatalov
Denis O. Shatalov
SKS. A. Kedik
S. A. Kedik
AAA. V. Aydakova
A. V. Aydakova
NZN. A. Zasypkina
N. A. Zasypkina
Branched oligohexamethyleneguanidine hydrochloride (OHMG) possesses great potential for the development of novel drugs for treatment of diseases caused by bacteria. This study aimed at evaluating antimicrobial activity of OHMG against potential causative agents of oral and pharyngeal mucosa infections, specifically, the activity against 56 clinical strains, 5 of which were antibiotics-resistant. Also, a preliminary in vivo study of specific activity of OHMG based on a traumatic stomatitis and gingivitis model in rabbits was carried out. In vitro antimicrobial activity of OHMG was determined by testing the minimal inhibitory concentration (MIC). OHMG displayed excellent activity against Streptococcus pneumoniae, Streptococcus pyogenes (MIC was 0.002-0.25 μg/ml), Moraxella catarrhalis (0.03-0.06 μg/ml), Neisseria gonorrhoeae (0.125-2 μg/ml). Almost complete healing of defects in the groups of animals within the 7-day application of "OHMG hydrochloride" at concentrations of 0.1% and 0.3% after the thermal formation of the stomatitis and gingivitis model was observed.